🚀 VC round data is live in beta, check it out!
Forte Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Forte Biosciences and similar public comparables like Atea Pharmaceuticals, Medy-Tox, Genfit, YungShin Global Holding and more.
Forte Biosciences Overview
About Forte Biosciences
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Founded
2007
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$389M
Forte Biosciences Financials
Forte Biosciences reported last 12-month revenue of —.
In the same LTM period, Forte Biosciences generated — in gross profit and had net loss of ($74M).
Revenue (LTM)
Forte Biosciences P&L
In the most recent fiscal year, Forte Biosciences reported revenue of — and EBITDA of ($71M).
Forte Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($71M) | XXX | XXX | XXX |
| Net Profit | ($74M) | XXX | ($69M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Forte Biosciences Stock Performance
Forte Biosciences has current market cap of $466M, and enterprise value of $389M.
Market Cap Evolution
Forte Biosciences' stock price is $33.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $389M | $466M | 27.8% | XXX | XXX | XXX | $-5.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialForte Biosciences Valuation Multiples
Forte Biosciences trades at (5.5x) EV/EBITDA.
EV / Revenue (LTM)
Forte Biosciences Financial Valuation Multiples
As of April 10, 2026, Forte Biosciences has market cap of $466M and EV of $389M.
Equity research analysts estimate Forte Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Forte Biosciences has a P/E ratio of (6.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $466M | XXX | $466M | XXX | XXX | XXX |
| EV (current) | $389M | XXX | $389M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | (5.2x) | XXX | (5.5x) | XXX | XXX | XXX |
| P/E | (6.3x) | XXX | (6.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Forte Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Forte Biosciences Margins & Growth Rates
Forte Biosciences' revenue in the last fiscal year grew by —.
Forte Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $5.0M for the same period.
Forte Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 93% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $5.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Forte Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Atea Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Genfit | XXX | XXX | XXX | XXX | XXX | XXX |
| YungShin Global Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Forte Biosciences M&A Activity
Forte Biosciences acquired XXX companies to date.
Last acquisition by Forte Biosciences was on XXXXXXXX, XXXXX. Forte Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Forte Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialForte Biosciences Investment Activity
Forte Biosciences invested in XXX companies to date.
Forte Biosciences made its latest investment on XXXXXXXX, XXXXX. Forte Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Forte Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Forte Biosciences
| When was Forte Biosciences founded? | Forte Biosciences was founded in 2007. |
| Where is Forte Biosciences headquartered? | Forte Biosciences is headquartered in United States. |
| How many employees does Forte Biosciences have? | As of today, Forte Biosciences has over 14 employees. |
| Who is the CEO of Forte Biosciences? | Forte Biosciences' CEO is Paul A. Wagner. |
| Is Forte Biosciences publicly listed? | Yes, Forte Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Forte Biosciences? | Forte Biosciences trades under FBRX ticker. |
| When did Forte Biosciences go public? | Forte Biosciences went public in 2020. |
| Who are competitors of Forte Biosciences? | Forte Biosciences main competitors are Atea Pharmaceuticals, Medy-Tox, Genfit, YungShin Global Holding. |
| What is the current market cap of Forte Biosciences? | Forte Biosciences' current market cap is $466M. |
| Is Forte Biosciences profitable? | No, Forte Biosciences is not profitable. |
| What is the current net income of Forte Biosciences? | Forte Biosciences' last 12 months net income is ($74M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.